JP6871232B2 - 新規結合ドメイン含有ポリペプチドおよびその使用 - Google Patents

新規結合ドメイン含有ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP6871232B2
JP6871232B2 JP2018503725A JP2018503725A JP6871232B2 JP 6871232 B2 JP6871232 B2 JP 6871232B2 JP 2018503725 A JP2018503725 A JP 2018503725A JP 2018503725 A JP2018503725 A JP 2018503725A JP 6871232 B2 JP6871232 B2 JP 6871232B2
Authority
JP
Japan
Prior art keywords
dbdpp
target
seq
amino acid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516092A (ja
JP2018516092A5 (OSRAM
Inventor
デビッド ウィリアム ラフレール
デビッド ウィリアム ラフレール
デビッド エム． ヒルベルト
デビッド エム． ヒルベルト
Original Assignee
サブドメイン リミテッド ライアビリティ カンパニー
サブドメイン リミテッド ライアビリティ カンパニー
アーセルクス インコーポレイテッド
アーセルクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サブドメイン リミテッド ライアビリティ カンパニー, サブドメイン リミテッド ライアビリティ カンパニー, アーセルクス インコーポレイテッド, アーセルクス インコーポレイテッド filed Critical サブドメイン リミテッド ライアビリティ カンパニー
Publication of JP2018516092A publication Critical patent/JP2018516092A/ja
Publication of JP2018516092A5 publication Critical patent/JP2018516092A5/ja
Priority to JP2021068754A priority Critical patent/JP7244567B2/ja
Application granted granted Critical
Publication of JP6871232B2 publication Critical patent/JP6871232B2/ja
Priority to JP2023007753A priority patent/JP2023052563A/ja
Priority to JP2024049923A priority patent/JP2024075751A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
JP2018503725A 2015-04-06 2016-04-04 新規結合ドメイン含有ポリペプチドおよびその使用 Active JP6871232B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021068754A JP7244567B2 (ja) 2015-04-06 2021-04-15 新規結合ドメイン含有ポリペプチドおよびその使用
JP2023007753A JP2023052563A (ja) 2015-04-06 2023-01-23 新規結合ドメイン含有ポリペプチドおよびその使用
JP2024049923A JP2024075751A (ja) 2015-04-06 2024-03-26 新規結合ドメイン含有ポリペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143772P 2015-04-06 2015-04-06
US62/143,772 2015-04-06
PCT/US2016/025868 WO2016164305A1 (en) 2015-04-06 2016-04-04 De novo binding domain containing polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068754A Division JP7244567B2 (ja) 2015-04-06 2021-04-15 新規結合ドメイン含有ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2018516092A JP2018516092A (ja) 2018-06-21
JP2018516092A5 JP2018516092A5 (OSRAM) 2019-05-09
JP6871232B2 true JP6871232B2 (ja) 2021-05-12

Family

ID=57072017

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018503726A Active JP6873101B2 (ja) 2015-04-06 2016-04-04 新規結合ドメイン含有ポリペプチドおよびその使用
JP2018503725A Active JP6871232B2 (ja) 2015-04-06 2016-04-04 新規結合ドメイン含有ポリペプチドおよびその使用
JP2021068754A Active JP7244567B2 (ja) 2015-04-06 2021-04-15 新規結合ドメイン含有ポリペプチドおよびその使用
JP2023007753A Withdrawn JP2023052563A (ja) 2015-04-06 2023-01-23 新規結合ドメイン含有ポリペプチドおよびその使用
JP2024049923A Pending JP2024075751A (ja) 2015-04-06 2024-03-26 新規結合ドメイン含有ポリペプチドおよびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018503726A Active JP6873101B2 (ja) 2015-04-06 2016-04-04 新規結合ドメイン含有ポリペプチドおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021068754A Active JP7244567B2 (ja) 2015-04-06 2021-04-15 新規結合ドメイン含有ポリペプチドおよびその使用
JP2023007753A Withdrawn JP2023052563A (ja) 2015-04-06 2023-01-23 新規結合ドメイン含有ポリペプチドおよびその使用
JP2024049923A Pending JP2024075751A (ja) 2015-04-06 2024-03-26 新規結合ドメイン含有ポリペプチドおよびその使用

Country Status (26)

Country Link
US (9) US10647775B2 (OSRAM)
EP (3) EP3280433B1 (OSRAM)
JP (5) JP6873101B2 (OSRAM)
KR (2) KR102788389B1 (OSRAM)
CN (4) CN107921090A (OSRAM)
AU (4) AU2016246426B2 (OSRAM)
BR (1) BR112017021308A2 (OSRAM)
CA (2) CA2981711A1 (OSRAM)
CY (1) CY1124453T1 (OSRAM)
DK (2) DK3280432T3 (OSRAM)
EA (1) EA201792226A1 (OSRAM)
ES (2) ES2901273T3 (OSRAM)
HR (1) HRP20210498T1 (OSRAM)
HU (1) HUE054435T2 (OSRAM)
IL (2) IL254907B (OSRAM)
LT (1) LT3280432T (OSRAM)
MX (2) MX387517B (OSRAM)
PH (1) PH12017501834B1 (OSRAM)
PL (1) PL3280432T3 (OSRAM)
PT (1) PT3280432T (OSRAM)
RS (1) RS61907B1 (OSRAM)
SG (2) SG10202007987QA (OSRAM)
SI (1) SI3280432T1 (OSRAM)
SM (1) SMT202100285T1 (OSRAM)
WO (3) WO2016164305A1 (OSRAM)
ZA (1) ZA201706875B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021106605A (ja) * 2015-04-06 2021-07-29 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907253VA (en) * 2017-02-10 2019-09-27 Dragonfly Therapeutics Inc Proteins binding bcma, nkg2d and cd16
AU2018217834A1 (en) * 2017-02-10 2019-08-22 Dragonfly Therapeutics, Inc. Proteins binding PSMA, NKG2D and CD16
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
IL263979B2 (en) * 2017-05-10 2023-09-01 Wellstat Immuno Therapeutics Llc Viruses with an envelope resistant to the immune system for cancer treatment
CN107216395B (zh) * 2017-07-03 2018-07-20 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
KR102783937B1 (ko) 2017-09-23 2025-03-24 메모리얼 슬로안 케터링 캔서 센터 A33 항체 조성물 및 방사면역요법에서 이를 사용하는 방법
EP3706801A4 (en) 2017-11-08 2022-04-06 L.E.A.F Holdings Group LLC PLATINUM COMPLEXES AND USES THEREOF
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL314701A (en) * 2017-11-14 2024-10-01 Arcellx Inc Multifunctional immune cell therapies
JP7285267B2 (ja) * 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
WO2019178518A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
MX2020011844A (es) 2018-05-08 2021-04-13 Amgen Inc Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53284A (fr) * 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201903479D0 (en) 2019-03-14 2019-05-01 Univ Oxford Innovation Ltd Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
JP2022527351A (ja) * 2019-04-02 2022-06-01 イーライ リリー アンド カンパニー 結合ペプチドを選択し検出するための方法
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN111848733B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 一种多肽组合物及疫苗
MX2021014334A (es) * 2019-05-24 2022-02-21 Avitide LLC Agentes afines a aav9.
CN114585918A (zh) 2019-05-31 2022-06-03 鲁比克治疗股份有限公司 中尺度工程化肽和选择方法
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
JPWO2021100585A1 (OSRAM) * 2019-11-20 2021-05-27
WO2021115333A1 (zh) * 2019-12-10 2021-06-17 苏州克睿基因生物科技有限公司 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
CN111560391B (zh) * 2020-05-21 2022-02-11 北京大学 一种蛋白质异质索烃的生物合成方法
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
EP4175656A4 (en) * 2020-07-03 2024-10-16 The Trustees of Columbia University in the City of New York POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA
CN114380907B (zh) * 2020-10-16 2024-06-18 中国科学院上海药物研究所 靶向cmtm6的纳米抗体及其制备方法和应用
EP4281566A1 (en) * 2021-01-20 2023-11-29 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
EP4313083A4 (en) 2021-03-26 2025-06-18 Arcellx, Inc. MULTIFUNCTIONAL IMMUNE CELL THERAPIES
AU2022388811A1 (en) * 2021-11-15 2024-05-16 Arcellx, Inc. D-domain containing polypeptides and uses thereof
CA3244527A1 (en) * 2022-02-18 2023-08-24 Dana-Farber Cancer Institute, Inc. CELL SURFACE RECEPTOR EPITOPE MODIFICATION
US12005082B2 (en) 2022-03-17 2024-06-11 Singular Immune, Inc. Composition and method of use recombinant fusion protein to generate CAR-immune cells
CA3256317A1 (en) * 2022-04-27 2023-11-02 Board Of Regents, The University Of Texas System CHIMERICAL ANTIGEN RECEPTORS BASED ON HINGE AND/OR TRANSMEMBRANE CD30 DOMAINS
CN115028689B (zh) * 2022-06-15 2023-05-30 浙江东方基因生物制品股份有限公司 特异性检测hpv6和hpv11的双特异性检测试剂盒
CN116380854B (zh) * 2023-03-06 2025-05-30 上海电力大学 一种基于荧光光谱快速检测水中微塑料污染的方法
WO2024254346A1 (en) * 2023-06-07 2024-12-12 The Broad Institute, Inc. Engineered viral like particles (evlps) for the selective transduction of target cells
WO2025122460A1 (en) * 2023-12-04 2025-06-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
DE19802708A1 (de) 1998-01-24 1999-07-29 Hoechst Marion Roussel De Gmbh Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren
CN1316910A (zh) 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
DE69940364D1 (de) 1999-05-18 2009-03-19 Dyax Corp Fab Fragmentbibliotheken und Verfahren für deren Verwendung
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US6815184B2 (en) 2000-07-31 2004-11-09 Biolex, Inc. Expression of biologically active polypeptide in duckweed
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ES2402527T3 (es) 2001-12-27 2013-05-06 Glycofi, Inc. Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética
WO2003061570A2 (en) 2002-01-16 2003-07-31 Zyomyx, Inc. Engineered binding proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003078614A2 (en) 2002-03-19 2003-09-25 Plant Research International B.V. Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants
KR101051245B1 (ko) 2002-09-06 2011-07-21 이소제니카 리미티드 시험관내 펩타이드 발현 라이브러리
ES2347325T3 (es) 2002-09-12 2010-10-28 Greenovation Biotech Gmbh Metodo de produccion de proteinas.
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2559409T3 (es) 2003-09-05 2016-02-12 Oregon Health & Science University Moléculas de MHC recombinantes monoméricas útiles para la manipulación de células T específicas de antígenos
EP1670931A2 (en) 2003-09-05 2006-06-21 GTC Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CN102989018A (zh) * 2005-08-03 2013-03-27 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
GB0907251D0 (en) * 2009-04-28 2009-06-10 Univ Leiden Coplymers
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
WO2012044999A2 (en) * 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012167109A2 (en) 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AU2013318928A1 (en) * 2012-09-21 2015-04-09 Kaneka Corporation Protein ligand for affinity isolation matrix
WO2014159947A1 (en) * 2013-03-14 2014-10-02 University Of Washington Through Its Center For Commercialization High affinity digoxigenin binding proteins
US20160031996A1 (en) * 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
GB201306634D0 (en) 2013-04-11 2013-05-29 Univ Bristol Cage-like particles
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
KR102788389B1 (ko) 2015-04-06 2025-03-31 서브도메인, 엘엘씨 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
KR20160126340A (ko) 2015-04-23 2016-11-02 삼성전자주식회사 3중-나선 다발 단백질 및 이의 용도
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
JP7305539B2 (ja) 2016-11-02 2023-07-10 ウニベルシテート バーゼル 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体
CN107254447B (zh) 2017-06-01 2020-10-16 刘未斌 Anti AFP CAR-T细胞及其制备方法和应用
JP7285267B2 (ja) 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL314701A (en) 2017-11-14 2024-10-01 Arcellx Inc Multifunctional immune cell therapies
EP4313083A4 (en) 2021-03-26 2025-06-18 Arcellx, Inc. MULTIFUNCTIONAL IMMUNE CELL THERAPIES
AU2022388811A1 (en) 2021-11-15 2024-05-16 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20250129817A (ko) 2022-11-29 2025-08-29 아르셀엑스, 인크. D-도메인 함유 폴리펩티드 및 그의 용도

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021106605A (ja) * 2015-04-06 2021-07-29 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
JP7244567B2 (ja) 2015-04-06 2023-03-22 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
JP2023052563A (ja) * 2015-04-06 2023-04-11 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
US12358995B2 (en) 2015-04-06 2025-07-15 Arcellx, Inc. De novo binding domain containing polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2018513212A (ja) 2018-05-24
BR112017021308A2 (pt) 2018-09-25
US12358995B2 (en) 2025-07-15
CN120424177A (zh) 2025-08-05
KR102788389B1 (ko) 2025-03-31
AU2016246426A1 (en) 2017-10-26
AU2021200810B2 (en) 2023-05-25
US20210002381A1 (en) 2021-01-07
JP7244567B2 (ja) 2023-03-22
MX387517B (es) 2025-03-18
CY1124453T1 (el) 2022-07-22
SMT202100285T1 (it) 2021-07-12
SG11201708257UA (en) 2017-11-29
HRP20210498T1 (hr) 2021-06-25
EP3280432B1 (en) 2021-03-10
US20210230288A1 (en) 2021-07-29
CA2981616C (en) 2025-06-17
EP3903804A1 (en) 2021-11-03
JP2024075751A (ja) 2024-06-04
EP3280432B8 (en) 2021-04-14
US20180251521A1 (en) 2018-09-06
KR20180012747A (ko) 2018-02-06
WO2016164308A1 (en) 2016-10-13
AU2016246426B2 (en) 2020-11-12
CA2981616A1 (en) 2016-10-13
AU2023219820A1 (en) 2023-09-07
CN107921090A (zh) 2018-04-17
US20180209983A1 (en) 2018-07-26
KR20250048140A (ko) 2025-04-07
MX2017012679A (es) 2018-02-09
SG10202007987QA (en) 2020-09-29
NZ736022A (en) 2024-02-23
PL3280432T3 (pl) 2021-09-27
PH12017501834A1 (en) 2018-04-23
IL254907B (en) 2021-05-31
US20250353920A1 (en) 2025-11-20
PH12017501834B1 (en) 2024-01-17
EP3280433A4 (en) 2018-10-31
US10647775B2 (en) 2020-05-12
ES2866202T3 (es) 2021-10-19
JP6873101B2 (ja) 2021-05-19
WO2016164369A2 (en) 2016-10-13
WO2016164305A1 (en) 2016-10-13
US20180251563A1 (en) 2018-09-06
MX2021013161A (es) 2021-12-10
US20200223934A1 (en) 2020-07-16
DK3280433T3 (da) 2021-11-15
ES2901273T3 (es) 2022-03-21
HUE054435T2 (hu) 2021-09-28
WO2016164369A3 (en) 2016-11-17
US11008397B2 (en) 2021-05-18
JP2023052563A (ja) 2023-04-11
IL254907A0 (en) 2017-12-31
AU2023219820B2 (en) 2025-01-30
EP3280432A1 (en) 2018-02-14
NZ774195A (en) 2024-09-27
CN115160438A (zh) 2022-10-11
SI3280432T1 (sl) 2021-09-30
PT3280432T (pt) 2021-04-22
US20200362046A1 (en) 2020-11-19
JP2018516092A (ja) 2018-06-21
JP2021106605A (ja) 2021-07-29
US10662248B2 (en) 2020-05-26
ZA201706875B (en) 2021-10-27
RS61907B1 (sr) 2021-06-30
CA2981711A1 (en) 2016-10-13
HK1249421A1 (en) 2018-11-02
AU2025202871A1 (en) 2025-05-15
CN107708720A (zh) 2018-02-16
AU2021200810A1 (en) 2021-03-04
IL282704A (en) 2021-06-30
DK3280432T3 (da) 2021-04-26
HK1249422A1 (en) 2018-11-02
EP3280432A4 (en) 2018-11-07
LT3280432T (lt) 2021-06-25
US20240043550A1 (en) 2024-02-08
EA201792226A1 (ru) 2018-08-31
EP3280433B1 (en) 2021-09-15
EP3280433A1 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
JP7244567B2 (ja) 新規結合ドメイン含有ポリペプチドおよびその使用
HK40061784A (en) De novo binding domain containing polypeptides and uses thereof
HK1249421B (en) De novo binding domain containing polypeptides and uses thereof
HK1249422B (en) De novo binding domain containing polypeptides and uses thereof
EA043883B1 (ru) Полипептиды, содержащие de novo связывающий домен, и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210415

R150 Certificate of patent or registration of utility model

Ref document number: 6871232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02